Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15408335 | 0.89 | LMNA (0.41) | PTGDR2CXCL8NOD1ALDH3A1MEN1 | |
| SCHEMBL15504622 | 0.87 | SRC (0.43) | PTGDR2SRCPDE4APDE4BPDE4C | |
| SCHEMBL24477091 | 0.86 | PTGDR2 (0.44) | PTGDR2SRCBRD4PIK3C3CXCL8 | |
| SCHEMBL5004901 | 0.85 | SRC (0.41) | PTGDR2SRCPDE4APDE4BPDE4C | |
| SCHEMBL30440833 | 0.85 | SRC (0.41) | PTGDR2SRCPDE4APDE4BPDE4C | |
| SCHEMBL5564252 | 0.85 | SRC (0.41) | PTGDR2SRCPDE4APDE4BPDE4C | |
| SCHEMBL3538021 | 0.84 | SRC (0.40) | PTGDR2SRCPDE4APDE4BPDE4C | |
| SCHEMBL1154907 | 0.81 | PTGDR2 (0.48) | PTGDR2SRCBRD4PIK3C3DCTPP1 | |
| SCHEMBL29959159 | 0.81 | PTGDR2 (0.48) | PTGDR2SRCBRD4PIK3C3DCTPP1 | |
| SCHEMBL20139600 | 0.80 | HTR1A (0.46) | PTGDR2SRCPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3641776-B1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230227458-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11702421-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | BIOMEA FUSION, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220169627-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC | 2022-06-02 | — | — | US | disclosed |
| US-11084825-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | BIOMEA FUSION, LLC (US) | 2021-08-10 | — | — | US | disclosed |
| US-10934300-B2 | Atropisomerism for enhanced kinase inhibitor selectivity | SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200223853-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC | 2020-07-16 | — | — | US | disclosed |
| US-20200165258-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-28 | — | — | US | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| CN-1125070-C | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| CN-1305480-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227458-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | PTGDR2 4038/4885SRC 3019/4885BRD4 58/4885 |
| US-10934300-B2 | Atropisomerism for enhanced kinase inhibitor selectivity | MAP2K2, MAP2K3, MAP3K20 | PTGDR2 2726/4885SRC 161/4885BRD4 837/4885 |
| US-11702421-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | PTGDR2 4317/4885SRC 2813/4885BRD4 60/4885 |
| US-11084825-B2 | Substituted pyridines as irreversible inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | PTGDR2 4250/4885SRC 1960/4885BRD4 22/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | PTGDR2 487/4885SRC 442/4885BRD4 888/4885 |
| US-20220169627-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | PTGDR2 4038/4885SRC 3019/4885BRD4 58/4885 |
| US-20200223853-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | PTGDR2 4038/4885SRC 3019/4885BRD4 58/4885 |
| US-20200165258-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | MAP2K2, MAP2K3, MAP3K20 | PTGDR2 2726/4885SRC 161/4885BRD4 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.